BTCC / BTCC Square / Global Cryptocurrency /
Obesity Drug Market Boom: Three Stocks Poised for Growth

Obesity Drug Market Boom: Three Stocks Poised for Growth

Published:
2025-10-20 12:44:01
19
2
BTCCSquare news:

The obesity drug sector has emerged as one of healthcare's most explosive growth opportunities, with sales projected to skyrocket from $15 billion in 2023 to $150 billion by 2035. Current-generation injectable therapies dominate, but oral formulations nearing approval could reshape the competitive landscape.

Eli Lilly (LLY) leads the U.S. market with its tirzeptatide-based drugs Mounjaro and Zepbound, boasting 1.1 million active prescriptions. The company's rapid market share gains come as competitors face manufacturing challenges. Lilly's pipeline includes orforglipron, a once-daily oral GLP-1 medication that could further solidify its position.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.